FILTER

Displaying 4121 - 4130 of 4156 publications

This study measures the monetary value households place on preventing malaria in Tigray, Ethiopia. We estimate a household demand function for a hypothetical malaria vaccine and compute the value of…

| Peer Reviewed |

In the summer of 2005, we interviewed 996 randomly selected respondents in Beira, Mozambique concerning their willingness and ability to pay for cholera vaccine for themselves and for other household…

| Peer Reviewed |

Many economic analyses of immunization programmes focus on the benefits in terms of public-sector cost savings, but do not incorporate estimates of the private cost savings that individuals receive…

| Peer Reviewed |

Although it is well known that vaccines against many infectious diseases confer positive economic externalities via indirect protection, analysts have typically ignored possible herd protection…

| Peer Reviewed |

We believe a lack of transparency undermines both the credibility of, and interest in, stated choice studies among policy makers. Unlike articles reporting the results of contingent valuation studies…

| Peer Reviewed |

This article considers the investment case for using the Vi polysaccharide vaccine in developing countries from two perspectives: reducing typhoid cases and limiting new health care spending. A case…

| Peer Reviewed |

Objectives: This study aims to measure the private demand for oral cholera vaccines in Hue, Vietnam, an area of relatively low endemicity of cholera, using the contingent valuation method. Methods…

| Peer Reviewed |

Previous studies have shown that cost of illness (COI) measures are lower than the conceptually correct willingness-to-pay (WTP) measure of the economic benefits of disease prevention. We compare COI…

| Peer Reviewed |

Data on the burden of disease, costs of illness, and cost-effectiveness of vaccines are needed to facilitate the use of available anti-typhoid vaccines in developing countries. This one-year…

| Peer Reviewed |